On Monday, Heritage Insurance Holdings Inc(NYSE:HRTG)’s shares declined -8.00% to $24.94.
Heritage Insurance Holdings, Inc. (HRTG), a property and casualty insurance holding company, will declare second quarter 2015 financial results after the market closes on Wednesday, August 5, 2015. A conference call to talk about the quarterly results will be held at 10:00 a.m. EDT on Thursday, August 6, 2015.
Heritage Insurance Holdings, Inc. operates as a property and casualty insurance holding company in the state of Florida. The company, through its partner, Heritage Property & Casualty Insurance Company, offers personal residential insurance for single-family homeowners and condominium owners; rental property insurance; and commercial residential insurance.
Zimmer Biomet Holdings Inc(NYSE:ZBH)’s shares gained 0.49% to $108.03.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) declared its second quarter 2015 sales and earnings conference call will be broadcast live over the Internet on Thursday, July 30, 2015, at 8 a.m. Eastern Time. A news release detailing the quarterly results will be made accessible at 7:30 a.m. Eastern Time the morning of the conference call.
Zimmer Biomet Holdings, Inc., together with its auxiliaries, designs, develops, manufactures, and markets orthopaedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. It offers orthopaedic reconstructive devices that restore function lost due to disease or trauma in joints comprising knees, hips, shoulders, and elbows; dental reconstructive implants, which restore function and aesthetics in patients who have lost teeth due to trauma or disease; spinal devices that are utilized by orthopedic surgeons and neurosurgeons for the treatment of degenerative diseases, deformities, and trauma in various regions of the spine; and trauma devices used primarily to reattach or stabilize damaged bone and tissue to support the bodys natural healing process.
At the end of Monday’s trade, Garmin Ltd.(NASDAQ:GRMN)‘s shares dipped -0.89% to $42.51.
Garmin Ltd. (GRMN) invites shareholders and investors to listen to its second quarter 2015 earnings conference call that will be broadcast over the internet on Wednesday, July 29, 2015 at 10:30 a.m. ET, with executives of Garmin. The call will be held in conjunction with the company’s earnings release, which will be distributed prior to market open on July 29, 2015.
Garmin Ltd., together with its auxiliaries, designs, develops, manufactures, and markets hand-held, wrist-based, and portable and fixed-mount global positioning system (GPS) enabled products; and other navigation, communication, and information products worldwide. It operates in five segments: Automotive/Mobile, Aviation, Marine, Outdoor, and Fitness.
Agenus Inc(NASDAQ:AGEN), ended its Monday’s trading session with 0.64% gain, and closed at $9.44.
Agenus Inc. (AGEN), an immunology company developing innovative treatments for cancers and other diseases, declared the appointment of C. Evan Ballantyne as the Company’s Chief Financial Officer, effective right away. Mr. Ballantyne will be responsible for all aspects of the Company’s financial, accounting, investor relations and corporate communication functions.
Mr. Ballantyne brings more than 30 years of financial and operations experience to Agenus. Most recently, Mr. Ballantyne served as the Chief Financial Officer at Synthetic Biologics, Inc., a publicly-traded biotechnology company, from February 2012 to May 2015. From August 2006 to April 2011, Mr. Ballantyne served as the Executive Vice President and Chief Financial Officer at Clinical Data, Inc., a publicly-traded biopharmaceutical company that was attained by Forest Laboratories, Inc. for $1.3 billion. Mr. Ballantyne has also served as the Chief Financial Officer at a number of private medical technology companies, counting Avedro, Inc. and ZymeQuest, Inc. Earlier in his career, he served as Vice President and Chief Operating Officer for ACNielsen Corporation - Europe Middle East & Africa, and he held the Chief Financial Officer position there as well for two years. He began his career at The Dun & Bradstreet Corporation where he held several senior financial positions. Mr. Ballantyne earned a B.A. from the University of Western Ontario, and took a post-graduate degree in Business Administration with Honors from the University of Windsor.
Agenus Inc., an immunotherapy company, engages in discovering and developing innovative treatments for patients with cancer and other diseases. Its treatments focus on providing therapeutic benefit through modulation of immune function. The company offers Retrocyte Display, a platform that screens and generates therapeutic antibody drug candidates focused on advancing checkpoint modulators using a high-throughput approach incorporating human antibody libraries expressed in mammalian B-lymphocytes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
